BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20363054)

  • 41. High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients.
    Matsue K; Aoki T; Odawara J; Fujiwara H; Iwama K; Kimura S; Yamakura M; Takeuch M
    Eur J Haematol; 2009 Oct; 83(4):357-64. PubMed ID: 19508685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
    Nebbia G; Garcia-Diaz A; Ayliffe U; Smith C; Dervisevic S; Johnson M; Gilson R; Tedder R; Geretti AM
    J Med Virol; 2007 Oct; 79(10):1464-71. PubMed ID: 17705185
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody].
    Ishihara T; Kanagawa M; Koyama J; Hasegawa K; Suzuki T; Hirayama Y; Terui T
    Rinsho Ketsueki; 2014 Nov; 55(11):2283-7. PubMed ID: 25501408
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab.
    Sera T; Hiasa Y; Michitaka K; Konishi I; Matsuura K; Tokumoto Y; Matsuura B; Kajiwara T; Masumoto T; Horiike N; Onji M
    Intern Med; 2006; 45(11):721-4. PubMed ID: 16819252
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma].
    Ono K; Iyama S; Matsunaga T; Sato T; Sato Y; Okuda T; Takada K; Kawano Y; Hayashi T; Miyanishi K; Sagawa T; Kobune M; Takimoto R; Kato J; Niitsu Y
    Gan To Kagaku Ryoho; 2007 Sep; 34(9):1509-12. PubMed ID: 17876158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease.
    Zachou K; Dalekos GN
    Liver Int; 2011 Mar; 31(3):277-9. PubMed ID: 21281426
    [No Abstract]   [Full Text] [Related]  

  • 48. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.
    Cheng AL; Hsiung CA; Su IJ; Chen PJ; Chang MC; Tsao CJ; Kao WY; Uen WC; Hsu CH; Tien HF; Chao TY; Chen LT; Whang-Peng J;
    Hepatology; 2003 Jun; 37(6):1320-8. PubMed ID: 12774010
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients.
    Li JM; Wang L; Shen Y; Xia ZG; Chen Y; Chen QS; Chen Y; Zeng XY; You JH; Qian Y; Shen ZX
    Ann Hematol; 2007 Sep; 86(9):639-45. PubMed ID: 17572895
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab.
    Miyagawa M; Minami M; Fujii K; Sendo R; Mori K; Shimizu D; Nakajima T; Yasui K; Itoh Y; Taniwaki M; Okanoue T; Yoshikawa T
    J Med Virol; 2008 Dec; 80(12):2069-78. PubMed ID: 19040281
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fatal hepatic failure caused by chemotherapy-induced reactivation of hepatitis B virus in a patient with hematologic malignancy.
    Sekine R; Taketazu F; Kuroki M; Takagi S; Imawari M; Kanazawa Y; Kawakami M
    Int J Hematol; 2000 Apr; 71(3):256-8. PubMed ID: 10846831
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.
    Mozessohn L; Chan KK; Feld JJ; Hicks LK
    J Viral Hepat; 2015 Oct; 22(10):842-9. PubMed ID: 25765930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.
    Koo YX; Tan DS; Tan IB; Tao M; Chow WC; Lim ST
    Cancer; 2010 Jan; 116(1):115-21. PubMed ID: 19899164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
    Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
    Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute liver failure related to chemotherapy.
    Wijaya I; Sanityoso A; Lesmana LA
    Acta Med Indones; 2012 Apr; 44(2):145-9. PubMed ID: 22745146
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
    Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
    Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection.
    Watanabe M; Shibuya A; Tsunoda Y; Danbara M; Ishii R; Ohsaka M; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Horie R; Higashihara M; Koizumi W
    Liver Int; 2011 Mar; 31(3):340-7. PubMed ID: 21134110
    [TBL] [Abstract][Full Text] [Related]  

  • 59. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
    Prieto M; Gómez MD; Berenguer M; Córdoba J; Rayón JM; Pastor M; García-Herola A; Nicolás D; Carrasco D; Orbis JF; Mir J; Berenguer J
    Liver Transpl; 2001 Jan; 7(1):51-8. PubMed ID: 11150423
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.